The lipid profile parameter in chronic obstructive pulmonary disease patients and correlation with severity of disease

Posted on by Muthanna Medical Journal

Research article

Volume 11, Issue 2,  2024.  Page 94-103    10.52113/1/1/2024-2-103

Authors
Hajir Ibraheem Makhlif Al-Taee *1 ,  Mohammed Waheeb Salman Al-Obaidi    

*Correspondence author: hajar.abd2202d@comed.uobaghdad.edu.iq

*1 College of Medicine, University of Baghdad, Baghdad, Iraq.
 Received 07 July 2024; revised 09 August 2024; accepted 11 September 2024, available online 04 October 2024.
Copyright © 2024 Al-Taee, et al. This is article distributed under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Abstract

COPD, a chronic respiratory illness with high mortality and morbidity worldwide, may be exacerbated by dyslipidemia. The aim of study is to assess prevalence of dyslipidemia in COPD patients and to evaluate its correlation with COPD severity. Between 2023 and 2024, Baghdad teaching hospital respiratory diseases outpatient clinic recruited 70 COPD patients for cross-sectional research. Anyone over 40 with COPD was sampled. Patients' lung function and lipid levels were documented. The study of 70 COPD patients found significant differences in demographics and clinical metrics across three severity groups (A, B, E). Key findings include higher mean age and lower mean FEV1/FVC% in the most severe group E, and significant correlations between lung function metrics (FEV1%, FEV1/FVC%, PEF%) and lipid profiles. Group E also exhibited the lowest serum HDL and highest triglycerides among the groups. In conclusion; Dyslipidemia is a common condition in COPD-patients that may correlate negatively with disease severity and lung functions.

Keywords: COPD dyslipidemia, lung functions, triglycerides

References

  1. Singh, D., Agusti, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. The European respiratory journal, 2019, 53(5), 1900164.
  2. Agarwal, A. K., Raja, et al. Chronic Obstructive Pulmonary Disease. 2023, In StatPearls. StatPearls Publishing.
  3. Silverman E. K.. Genetics of COPD. Annual review of physiology, 2020, 82, 413–431.
  4. Torres-Durán, M., Lopez-Campos, et al. Alpha-1 antitrypsin deficiency: outstanding questions and future directions. Orphanet journal of rare diseases, 2018, 13(1), 114.
  5. Sanduzzi, A., Ciasullo, et al. Alpha-1-Antitrypsin Deficiency and Bronchiectasis: A Concomitance or a Real Association?. International journal of environmental research and public health, 2020, 17(7), 2294.
  6. Tageldin, M. A., Nafti, et al. Distribution of COPD-related symptoms in the Middle East and North Africa: results of the BREATHE study. Respiratory medicine, 2012, 106 Suppl 2, S25–S32. https://doi.org/10.1016/S0954-6111(12)70012-4.
  7. Al Lami, F., & Salim, Z. Prevalence and determinants of chronic obstructive pulmonary disease among a sample of adult smokers in Baghdad, Iraq, 2014. Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit, 2017, 23(2), 67–72.
  8. Parker, C. M., Voduc, et al. Physiological changes during symptom recovery from moderate exacerbations of COPD. The European respiratory journal, 2005, 26(3), 420–428.
  9. Hsu, E., & Bajaj, T. Beta2-Agonists. 2023, In StatPearls. StatPearls Publishing.
  10. Rabe K. F. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. British journal of pharmacology, 2011, 163(1), 53–67.
  11. Uzun, S., Djamin, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. The Lancet. Respiratory medicine,2014, 2(5), 361–368.
  12. Li, C. L., Lin, et al. Using the BODE Index and Comorbidities to Predict Health Utilization Resources in Chronic Obstructive Pulmonary Disease. International journal of chronic obstructive pulmonary disease, 2020, 15, 389–395.
  13. Decramer, M., Janssens, W., & Miravitlles, M. Chronic obstructive pulmonary disease. Lancet (London, England), 2012, 379(9823), 1341–1351.
  14. Berberich, A. J., & Hegele, R. A. A Modern Approach to Dyslipidemia. Endocrine reviews, 2022, 43(4), 611–653.
  15. Hedayatnia M, Asadi Z, Zare-Feyzabadi R, et al. Dyslipidemia and cardiovascular disease risk among the MASHAD study population. Lipids Health Dis. 2020;19(1):42. Published 2020 Mar 16. doi:10.1186/s12944-020-01204-y
  16. Osman, S., Ziegler, et al. The Association between Risk Factors and Chronic Obstructive Pulmonary Disease in Canada: A Cross-sectional Study Using the 2014 Canadian Community Health Survey. International journal of preventive medicine, 2017, 8, 86.
  17. Yang, Y., Li, et al. Early COPD Risk Decision for Adults Aged From 40 to 79 Years Based on Lung Radiomics Features. Frontiers in medicine, 2022, 9, 845286.
  18. Sharma, G., & Goodwin, J. Effect of aging on respiratory system physiology and immunology. Clinical interventions in aging, 2006, 1(3), 253–260.
  19. Ntritsos, G., Franek, et al. Gender-specific estimates of COPD prevalence: a systematic review and meta-analysis. International journal of chronic obstructive pulmonary disease, 2018, 13, 1507–1514.
  20. Adeloye, D., Chua, et al. Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. Journal of global health, 2015, 5(2), 020415.
  21. Xuan L, Han F, Gong L, et al. Association between chronic obstructive pulmonary disease and serum lipid levels: a meta-analysis. Lipids Health Dis. 2018;17(1):263. Published 2018 Nov 21. doi:10.1186/s12944-018-0904-4
  22. DeMeo, D. L., Ramagopalan, et al. Women manifest more severe COPD symptoms across the life course. International journal of chronic obstructive pulmonary disease, 2018, 13, 3021–3029.
  23. Celli, B., Vestbo, et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. American journal of respiratory and critical care medicine, 2011, 183(3), 317–322.
  24. Dirks, M. L., Wall, et al. One Week of Bed Rest Leads to Substantial Muscle Atrophy and Induces Whole-Body Insulin Resistance in the Absence of Skeletal Muscle Lipid Accumulation. Diabetes, 2016, 65(10), 2862–2875.
  25. Sangroula, P., Ghimire, et al. Correlation of Body Mass Index and Oxygen Saturation in Chronic Obstructive Pulmonary Disease Patients at a Tertiary Care Center in Nepal: A Cross-Sectional Study. International journal of chronic obstructive pulmonary disease, 2023, 18, 1413–1418.
  26. Markelić, I., Hlapčić, et al. Lipid profile and atherogenic indices in patients with stable chronic obstructive pulmonary disease. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2021, 31(1), 153–161.
  27. Xuan, L., Han, et al. Association between chronic obstructive pulmonary disease and serum lipid levels: a meta-analysis. Lipids in health and disease, 2018, 17(1), 263.
  28. Zafirova-Ivanovska, B., Stojkovikj, et al. The Level of Cholesterol in COPD Patients with Severe and Very Severe Stage of the Disease. Open access Macedonian journal of medical sciences, 2016, 4(2), 277–282.

Volume 10, Issue 2, 2023

 

 

 

 

 

Volume 11, Issue 2, 2024

Downloads: 336

Al-Taee H,Al-Obaidi MW. The lipid profile parameter in Chronic obstructive pulmonary disease patients and correlation with severity of disease. Muthanna Medical Journal. 2024; 11(2):94-103.